International coverage of treatments and trials, with the ability to zoom in on countries we cover. From approved options to compassionate access.
Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration
FDA approval on 24 July 2026 for Lytenava (bevacizumab-vikg) injection — an ophthalmic VEGF inhibitor for intravitreal use — for neovascular…
This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava…
Foundayo (orforglipron) for chronic weight management
FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight management and type 2 diabetes — those lines stay…
FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight…
Lynavoy (linerixibat) for cholestatic itch in adults with primary biliary cholangitis — oral IBAT inhibitor
The FDA (17 Mar 2026) and UK MHRA (1 May 2026) labelled an oral 40 mg tablet twice daily for cholestatic pruritus associated with primary biliary…
The FDA (17 Mar 2026) and UK MHRA (1 May 2026) labelled an oral 40 mg tablet twice daily for cholestatic…
Jascayd (nerandomilast) for IPF and PPF
The FDA, Europe, and the UK have labelled nerandomilast for adults with idiopathic pulmonary fibrosis and for adults with progressive pulmonary fibrosis.…
The FDA, Europe, and the UK have labelled nerandomilast for adults with idiopathic pulmonary fibrosis and for…
Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy
The FDA, Europe, the UK, and China have labelled aficamten for symptomatic obstructive HCM in adults. England's NHS has a 30-day funding clock from NICE.…
The FDA, Europe, the UK, and China have labelled aficamten for symptomatic obstructive HCM in adults.…